Lead­ing pro­teomics play­er gets a trio of new part­ners; GV tries to pre­vent cer­vi­cal can­cer

A lit­tle over 6 months ago, John Bak­er got on a call from a CEO with a strange re­quest.

Bak­er is head of in­no­va­tion at Ab­cam, a British com­pa­ny that pro­vides life sci­ence re­search tools to labs and com­pa­nies around the world. A lot of the firm’s work in­volves sup­ply­ing high­ly spe­cif­ic an­ti­bod­ies that al­low sci­en­tists to de­tect the pres­ence of or fish out a spe­cif­ic pro­tein in a sam­ple.

Su­jal Pa­tel, CEO of Nau­tilus Biotech­nol­o­gy, want­ed ba­si­cal­ly the op­po­site. “Their first call to us was, ‘Hey, guys, we’re look­ing for some re­al­ly bad an­ti­bod­ies,’” Bak­er re­called. “‘What have you got be­yond trench­ing in a freez­er for things that had failed?’”

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.